Marker Therapeutics, Inc.
MRKR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 43.2% | 146.7% | -84.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | 100% | -385% | -798.1% | -125.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | -$0 | -$0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -173.3% | -494.8% | -1,320.1% | -171.5% |
| Other Income/Exp. Net | $0 | $0 | $0 | $0 |
| Pre-Tax Income | -$0 | -$0 | -$0 | -$0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -162.1% | -466.3% | -1,273.6% | -170.4% |
| EPS | -0.12 | -0.29 | -0.4 | -0.42 |
| % Growth | 58.6% | 27.5% | 4.8% | – |
| EPS Diluted | -0.12 | -0.29 | -0.4 | -0.42 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | -$0 | $0 | $0 | -$0 |
| EBITDA | -$0 | -$0 | $0 | -$0 |
| % Margin | -162.1% | -494.8% | 0% | -171.5% |